ARTICLE | Product Development
With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment
The BLyS inhibitor could become the first drug for lupus nephritis, which affects about 1 million patients
June 4, 2020 8:44 AM UTC
Newly presented Phase III data burnish GSK’s case for a regulatory submission planned for this month seeking to expand the label of lupus drug Benlysta to include lupus nephritis.
Richard Furie, the lead investigator of the BLISS-LN trial, told BioCentury that although lupus nephritis is a complication of systemic lupus erythematosis (SLE), for which Benlysta belimumab is already approved, the two disorders are treated differently. Furie is chief of the rheumatology division and professor at the Feinstein Institutes at Northwell Health...